Your session is about to expire
← Back to Search
Monoclonal Antibodies
RO7589831 for Solid Tumors
Phase 1
Recruiting
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at prespecified timepoints in cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Awards & highlights
Study Summary
This trial tests a new drug for advanced solid tumors, to see if it's safe and effective.
Who is the study for?
This trial is for adults with advanced solid tumors that are microsatellite instability (MSI) and/or deficient mismatch repair (dMMR). Participants must have measurable disease, be in good general health with a performance status score of 0 or 1, and have tried at least one standard treatment without success. They should not have any major infections, uncontrolled diabetes, CNS metastases requiring steroids or anticonvulsants, or known Werner syndrome.Check my eligibility
What is being tested?
The study tests RO7589831, an oral drug targeting the WRN protein to potentially stop the growth of MSI/dMMR cancers. It's a Phase I trial involving dose-escalation and expansion to assess safety, tolerability, how the body processes the drug (pharmacokinetics), its effects on cancer cells (pharmacodynamics), and initial effectiveness against tumors.See study design
What are the potential side effects?
Potential side effects aren't specified but may include typical reactions to new cancer drugs such as nausea, fatigue, allergic reactions to ingredients in the pill form of RO7589831. Since it's a first-in-human study assessing safety/tolerability is a primary goal.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at prespecified timepoints in cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at prespecified timepoints in cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0)
Incidence of Dose-Limiting Toxicities
Secondary outcome measures
Apparent Oral Clearance (CL/F) of RO7589831
Area Under the Plasma Concentration-Time Curve (AUC) of RO7589831
Disease Control Rate
+8 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Part II: RO7589831 Dose ExpansionExperimental Treatment1 Intervention
Group II: Part I: RO7589831 Dose EscalationExperimental Treatment1 Intervention
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
RO7589831, a Werner (WRN) protein inhibitor, targets the WRN protein involved in DNA repair and replication, aiming to block the growth of tumors with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR). This targeted approach is crucial for patients with these specific tumor types as it offers a potentially more effective treatment.
Other common treatments for solid tumors include chemotherapy, which kills rapidly dividing cells; immunotherapy, which enhances the immune system's ability to fight cancer; and targeted therapies that inhibit specific molecules driving tumor growth. Understanding these mechanisms allows for personalized treatment strategies, improving patient outcomes.
Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
Find a Location
Who is running the clinical trial?
Hoffmann-La RocheLead Sponsor
2,434 Previous Clinical Trials
1,091,172 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,202 Previous Clinical Trials
889,816 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger